Late filing
elevated
Filing comparison
Quince Therapeutics, Inc. told the SEC it could not file its annual report on time
Does not expect a significant change in results. 1 day past the statutory due date.
(the “Company”), was unable to file its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”) within the prescribed time period as additional time is necessary to complete accounting procedures and prepare required disclosures, due to recent reductions in headcount and the impacts of the recently announced negative results of the Company’s Phase 3 clinical trial. As previously disclosed, the Company’s pivotal Phase 3 international, multicenter, randomized, double-blind, placebo-controlled study, the primary endpoint, which measured the change from baseline to last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating…
Evidence
- Anticipates significant change
- No
- Days past due date
- 1
- Other periodic reports filed
- Yes
- Routine
- No
- Severity
- elevated
- Source
- Form 12b-25 (notification of late filing)
- Stated reason
- (the “Company”), was unable to file its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”) within the prescribed time period as additional time is necessary to complete accounting procedures and prepare required disclosures, due to recent reductions in headcount and the impacts of the recently announced negative results of the Company’s Phase 3 clinical trial. As previously disclosed, the Company’s pivotal Phase 3 international, multicenter, randomized, double-blind, placebo-controlled study, the primary endpoint, which measured the change from baseline to last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating…
- Why
- The company told the SEC it could not file a periodic report on time, using Form 12b-25.